多西紫杉醇联合GP化疗方案对晚期非小细胞肺癌患者炎性因子、免疫功能及临床症状的影响

目的 探讨多西紫杉醇联合吉西他滨+顺铂(GP)化疗方案对晚期非小细胞肺癌患者炎性因子、免疫功能及临床症状的影响.方法 回顾性分析40例晚期非小细胞肺癌患者的临床资料,所有患者均接受多西紫杉醇联合GP化疗方案,化疗2个周期后,比较化疗前后患者的血清炎性因子、免疫功能及临床症状.结果 化疗2个周期后,患者的血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、C-反应蛋白(CRP)浓度明显低于化疗前(P﹤0.01);CD3+、CD4+、CD4/CD8水平高于化疗前,CD8+水平低于化疗前,差异均有统计学意义(P﹤0.05);癌因性疲乏、局部疼痛及食欲不振评分均明显低于化疗前(P﹤0.01).结论 多西紫杉醇联合GP化疗方案能有效缓解晚期非小细胞肺癌患者的临床症状,可能与降低血清炎性因子水平、改善免疫功能等因素有关.

The impact of docetaxel combined with GP chemotherapy on inflammatory factor,immune function and clinical symptoms in patients with advanced non-small cell lung cancer

Objective To study the effect of docetaxel combined with gemcitabine+cisplatin(GP)chemotherapy on the inflammatory factor, immune function and clinical symptoms in patients with advanced non-small cell lung cancer (NSCLC).Method The clinical data of 40 cases of NSCLC were analyzed retrospectively,all patients were given GP+docetaxel chemotherapy, after 2 cycles of chemotherapy, the inflammatory factor, immune function and clinical symp-toms before and after chemotherapy were compared.Result After two cycles of chemotherapy,the serum TNF-α,IL-6, CRP were significantly decreased in all patients(P<0.01);while CD3+,CD4+,CD4/CD8 were significantly higher than that before chemotherapy, CD8+was significantly lower than that before chemotherapy, with significant difference ob-served(P<0.05);the scores for cancer-related fatigue,local pain,loss of appetite were significantly lower that those be-fore chemotherapy (P<0.01). Conclusion Docetaxel combined with GP chemotherapy regimens help to alleviate the clinical symptoms of patients with advanced NSCLC,which may be related to the reduction of serum inflammatory fac-tors,and the improvement of immune functions.